文献速递消化道肿瘤与早癌

外源性、内源性、肿瘤和免疫因素的综合分析用于精准医学

Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine.
PubMed 文献 · Gut · 2018-02-06

本文提出将肿瘤免疫学整合入人群健康科学的分子病理流行病学(MPE)框架,利用生物信息学、体内病理学和组学技术,结合组织、外周血循环细胞、无细胞血浆、粪便、痰、尿等标本,分析饮食、营养、酒精、吸烟、肥胖、生活方式、环境暴露和微生物组等外源性与内源性因素及胚系遗传(如HLA基因型)与肿瘤免疫特征的关联;胃肠道肿瘤因肠道微生物丰富、免疫组织多及肠道炎症致癌作用明确而成为该模型的典范疾病;结直肠癌原理验证研究揭示阿司匹林、维生素D、炎症饮食和ω-3多不饱和脂肪酸的免疫调节作用。

要点

  • 分子病理流行病学(MPE)框架可将肿瘤免疫学整合入人群健康科学,连接暴露与胚系遗传至肿瘤及免疫特征。
  • 胃肠道肿瘤因肠道微生物丰富、免疫组织多及肠道炎症致癌作用明确,是该免疫-MPE模型的典范疾病。
  • 结直肠癌原理验证研究提示阿司匹林、维生素D、炎症饮食和ω-3多不饱和脂肪酸具有免疫调节作用。

核心结论

  • 整合免疫-MPE模型有助于更好地理解环境-肿瘤-免疫相互作用,并为精准医学提供有效的免疫预防和免疫治疗策略。

研究设计与样本

  • 本文为综述,提出分子病理流行病学(MPE)跨学科研究框架,以整合肿瘤免疫学与人群健康科学。
  • 多水平研究可利用生物信息学、体内病理学和组学(基因组学、表观基因组学、转录组学、蛋白质组学和代谢组学)技术,使用组织、外周血循环细胞、无细胞血浆、粪便、痰、尿和其他体液标本。

主要发现

  • 针对CTLA4和CD274(程序性细胞死亡1配体1,PD-L1)/PDCD1(程序性细胞死亡1,PD-1)T细胞共受体通路的免疫检查点免疫治疗策略正在革新肿瘤学。
  • 美国食品药品监督管理局批准帕博利珠单抗用于高度微卫星不稳定或错配修复缺陷的实体瘤,凸显精准免疫肿瘤学的前景。
  • 尽管有证据表明饮食、营养、酒精、吸烟、肥胖、生活方式、环境暴露和微生物组等外源性和内源性因素影响肿瘤-免疫相互作用,但这些因素与免疫的综合分析仍滞后。
  • 肿瘤微环境中的免疫细胞分析尚未充分整合入大规模研究。
  • 结直肠癌原理验证研究揭示了阿司匹林、维生素D、炎症饮食和ω-3多不饱和脂肪酸的免疫调节作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunotherapy strategies targeting immune checkpoints such as the CTLA4 and CD274 (programmed cell death 1 ligand 1, PD-L1)/PDCD1 (programmed cell death 1, PD-1) T-cell coreceptor pathways are revolutionising oncology. The approval of pembrolizumab use for solid tumours with high-level microsatellite instability or mismatch repair deficiency by the US Food and Drug Administration highlights promise of precision immuno-oncology. However, despite evidence indicating influences of exogenous and endogenous factors such as diet, nutrients, alcohol, smoking, obesity, lifestyle, environmental exposures and microbiome on tumour-immune interactions, integrative analyses of those factors and immunity lag behind. Immune cell analyses in the tumour microenvironment have not adequately been integrated into large-scale studies. Addressing this gap, the transdisciplinary field of molecular pathological epidemiology (MPE) offers research frameworks to integrate tumour immunology into population health sciences, and link the exposures and germline genetics (eg, HLA genotypes) to tumour and immune characteristics. Multilevel research using bioinformatics, in vivo pathology and omics (genomics, epigenomics, transcriptomics, proteomics and metabolomics) technologies is possible with use of tissue, peripheral blood circulating cells, cell-free plasma, stool, sputum, urine and other body fluids. This immunology-MPE model can synergise with experimental immunology, microbiology and systems biology. GI neoplasms represent exemplary diseases for the immunology-MPE model, given rich microbiota and immune tissues of intestines, and the well-established carcinogenic role of intestinal inflammation. Proof-of-principle studies on colorectal cancer provided insights into immunomodulating effects of aspirin, vitamin D, inflammatory diets and omega-3 polyunsaturated fatty acids. The integrated immunology-MPE model can contribute to better understanding of environment-tumour-immune interactions, and effective immunoprevention and immunotherapy strategies for precision medicine.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Ogino S, Nowak JA, Hamada T, et al. Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. Gut. 2018. PMID: 29437869. doi:10.1136/gutjnl-2017-315537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。